Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announces that it has entered into a definitive agreement to be acquired by Kuva Labs Inc. (”Kuva”), a privately-held company. Under the terms of the merger agreement, Kuva will commence a tender offer to acquire all the issued and outstanding shares of common stock of the Company for $5.00 per share in cash payable at closing plus one contingent value right (“CVR”) per share (the “Transaction”).
Read the full article: Lisata Therapeutics Enters into Definitive Agreement to Be Acquired by Kuva Labs, Inc. //
Source: https://www.globenewswire.com/news-release/2026/03/06/3251364/18623/en/Lisata-Therapeutics-Enters-into-Definitive-Agreement-to-be-Acquired-by-Kuva-Labs-Inc.html